stockrow
Saturday 7 November 2026
Export AZTR’s income statement to Excel — free account
Azitra, Inc.
AZTR Healthcare Biotechnology
Azitra, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $7,500.00, down 98.9% from fiscal 2023.
- EPS
- +85.3%
- Free cash flow
- −19.6%
Quarter to June 2026, against a year earlier
0.75
0.02
+2.74%
Follow AZTR
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
— | — | — | — |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
0.79 | 2.07 | 6.59 | 4.49 | |
Current Ratio |
1.23 | 2.83 | 6.94 | 4.86 | |
Net Debt/EBITDA |
0.53 | 0.98 | 3.15 | 2.04 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.88 | 1.30 | 0.63 | 0.98 | |
Capex/Depreciation |
(0.37) | (0.74) | (0.05) | (1.04) | |
Interest Coverage |
(6,921.25) | (404.84) | (1,157.03) | (2,442.29) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.06 | 0.06 | 0.03 | 0.04 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(5.94) | (5.93) | (1.60) | (1.71) | |
Capex per Share |
(0.10) | (0.17) | (0.02) | (0.06) | |
Free Cash Flow per Share |
(6.04) | (6.11) | (1.62) | (1.77) | |
Cash per Share |
3.40 | 4.24 | 6.48 | 3.49 | |
Shareholders Equity per Share |
5.53 | 7.80 | 6.75 | 3.80 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
5.53 | 7.80 | 6.75 | 3.80 | |
Free Cash Flow |
(2.49) | (2.98) | (2.51) | (3.41) | |
Working Capital |
0.42 | 1.95 | 9.21 | 5.91 | |
Capital Expenditures |
(0.04) | (0.08) | (0.04) | (0.12) | |
Net Current Asset Value |
0.21 | 1.80 | 9.11 | 5.86 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.01 | 0.12 | 0.13 | 0.11 | |
Average Payables |
0.65 | 0.44 | 0.75 | 0.57 | |
Average Assets |
7.04 | 6.19 | 9.02 | 6.44 | |
Average Common Equity |
5.17 | 4.75 | 7.44 | 4.78 |
Columns are period end dates · fundamentals updated 2 Nov 2026